Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY2023 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, May 19, 2023
Slide 1: Investor Presentation Q4FY23
Investor Presentation Q4FY23 May 19, 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of FY23
Key Highlights of FY23 • Revenue from Operation grew by 9.1% during FY23, with EBITDA margin of 13.9% and Net Profit margin of 8.5% • India Business: As per IQVIA, Company’s sales in FY23 registered growth of 12.8% compared to IPM growth of 7.9% • Outperformed IPM growth by 498 basis points in FY23
Slide 4: Key Financial Highlights – Q4FY23 (Consolidated)
Key Financial Highlights – Q4FY23 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 20,113 17,187 29,026 24,839 Q4FY22 Q4FY23 International sales 8,570 7,411 Q4FY22 Q4FY23 Q4FY22 Q4FY23
Slide 5: Key Financial Highlights – Q4FY23 (Consolidated)
Key Financial Highlights – Q4FY23 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 16,471 3,372 3,533 14,525 58.5% 56.7% 13.6% 12.2% Q4FY22 Q4FY23 Q4FY22 Q4FY23 PBT (after exceptional item) PAT (after Minority Interest) Q4FY23 was impacted by exceptional item
Slide 6: Key Financial Highlights – FY23 (Consolidated)
Key Financial Highlights – FY23 (Consolidated) All figures in ₹ mn Particulars (₹ mn) FY23 FY22 YoY growth Revenue from Operations 115,993 106,342 9.1% Gross Profit 66,924 64,539 3.7% Gross Profit margin 57.7% 60.7% EBITDA 16,095 20,529 -21.6% EBITDA margin 13.9% 19.3% PBT before exceptional item 14
Slide 7: India Business
India Business India Business: Q4FY23 Sales of ₹ 20,113 million (17.0% YoY growth) • India sales contributed 70.1% to total sales in Q4FY23 • As per IQVIA, In Q4FY23, the Company’s secondary sales grew by 22.5% significantly outperforming IPM growth of 14.9% YoY. • Exceptional performance across all
Slide 8: Secondary Sales Performance
Secondary Sales Performance Exemplary Performance in Almost Every Therapy in FY23 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 17.5% 18.4% 12.3% 12.4% 8.6% 6.2% 2.5% 3.5% Alkem sales growth YoY1,2 Indian pharma industry sales g
Slide 9: US Business
US Business US Business: Q4FY23 Sales of ₹ 5,916 million (9.2% YoY growth) • US sales contributed 20.6% to total sales in Q4FY23 • During the quarter, the US business registered growth in ₹ terms mainly on account of currency depreciation. • In Q4FY23, the Company filed 4 ANDAs with the US FDA and r
Slide 10: US Business: Update on US FDA inspections
US Business Update on US FDA inspections Facility Capability Last inspection Status post last inspection Ankleshwar (India) API April 2023 Successfully closed inspection without any observations. St. Louis (US) Formulations November 2022 Inspection is closed. EIR# received in December 2022 Bioequiva
Slide 11: Other International Business
Other International Business Other International Business: Q4FY23 Sales of ₹ 2,654 million (33.3% YoY growth) • Other International Market sales contributed 9.3 % to total sales in Q4FY23 • The Company has presence in Latin America, Australia, Europe, South East Asia, Africa and CIS. • All our major
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on March 31, 2023 Non-Institution, 21.70% Promoter & Promoter Group, 57.16% Institution, 21.14% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bodi
Slide 13: Thank You
Thank You For further information or queries, please contact Amit Kumar Khandelia AVP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com